iRhythm Technologies (NASDAQ:IRTC) EVP Mervin Smith Sells 1,352 Shares

iRhythm Technologies (NASDAQ:IRTC) EVP Mervin Smith sold 1,352 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total value of $173,650.88. Following the completion of the sale, the executive vice president owned 25,612 shares of the company’s stock, valued at $3,289,605.28. The trade was a 5.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mervin Smith also recently made the following trade(s):

• On Wednesday, February 25th, Mervin Smith sold 4,041 shares of iRhythm Technologies stock. The stock was sold at an average price of $135.42, for a total value of $547,232.22.
• On Tuesday, February 24th, Mervin Smith sold 732 shares of iRhythm Technologies stock. The shares were sold at an average price of $140.91, for a total transaction of $103,146.12.

iRhythm Technologies Trading Down 2.0%

IRTC stock traded down $2.61 on Tuesday, reaching $125.85. The company’s stock had a trading volume of 593,038 shares, compared to its average volume of 724,545. The firm has a market cap of $4.07 billion, a PE ratio of -89.89 and a beta of 1.09. The business has a fifty day simple moving average of $159.40 and a two-hundred day simple moving average of $170.14. iRhythm Technologies has a 12-month low of $92.52 and a 12-month high of $212.00. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The business had revenue of $208.89 million during the quarter, compared to the consensus estimate of $202.61 million. During the same quarter in the prior year, the company earned ($0.04) earnings per share. The firm’s quarterly revenue was up 27.1% compared to the same quarter last year. As a group, research analysts forecast that iRhythm Technologies will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their target price on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a report on Friday, February 20th. JPMorgan Chase & Co. reduced their price objective on iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Evercore raised iRhythm Technologies from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $194.00 to $210.00 in a report on Monday, January 5th. Morgan Stanley restated an “overweight” rating on shares of iRhythm Technologies in a report on Monday, January 12th. Finally, Wall Street Zen upgraded shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $211.62.

Hedge Funds Weigh In On iRhythm Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of iRhythm Technologies by 48.4% in the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after acquiring an additional 60 shares during the period. Ascent Group LLC boosted its holdings in iRhythm Technologies by 0.7% in the fourth quarter. Ascent Group LLC now owns 9,587 shares of the company’s stock worth $1,701,000 after purchasing an additional 70 shares during the last quarter. WoodTrust Financial Corp grew its position in iRhythm Technologies by 0.7% in the 4th quarter. WoodTrust Financial Corp now owns 10,070 shares of the company’s stock worth $1,787,000 after purchasing an additional 70 shares during the period. US Bancorp DE raised its stake in iRhythm Technologies by 7.8% during the 3rd quarter. US Bancorp DE now owns 1,042 shares of the company’s stock valued at $179,000 after buying an additional 75 shares during the last quarter. Finally, State of Wyoming lifted its holdings in shares of iRhythm Technologies by 16.0% during the 4th quarter. State of Wyoming now owns 616 shares of the company’s stock valued at $109,000 after buying an additional 85 shares during the period.

Key iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Company guidance: iRhythm updated FY‑2026 revenue guidance to $870.0M–$880.0M, noticeably above the consensus (~$817.3M). Higher top‑line guidance is a positive signal for growth and revenue cadence even though EPS guidance was not specified in the release.
• Neutral Sentiment: Analyst/market note: Coverage is shifting as targets are being reset while management’s guidance holds — a thematic piece that explains why price targets and sentiment may be changing even with stronger revenue guidance. How The iRhythm Holdings (IRTC) Story Is Shifting As Targets Reset And Guidance Holds
• Negative Sentiment: Insider selling: Multiple senior execs sold shares on March 2 — including the CAO, several EVPs and other insiders — totaling ~17,826 shares for roughly $2.29M in proceeds (average price ≈ $128.44). Each reported a mid-single-digit percentage reduction in their holdings; insiders still retain substantial stakes but the clustered selling can be perceived negatively by the market. Representative SEC filing: Insider Form 4

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.